



QT IMAGING

Quantitative Transmission Imaging

Breast Acoustic CT™ Scanner

December 2025



Disclaimer

ABOUT THIS PRESENTATION

This investor presentation (this "Presentation") is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the "Company", "QT Imaging Holdings", "QTI"), nor its respective directors, officers, employees, agents, advisors or affiliates, including QT Imaging, Inc. ("QT Imaging"), makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation, which has not been verified and is subject to change at any time. Viewers of this Presentation should each make their own evaluation of QT Imaging Holdings and of the relevance and accuracy of the information and should make such other investigations as they deem necessary. To the fullest extent permitted by law, no responsibility or liability whatsoever is accepted by QT Imaging Holdings, or its directors, officers, employees, agents, advisors or affiliates for any loss howsoever arising, directly or indirectly, from any use of this Presentation or such information or opinions contained herein or otherwise arising in connection therewith.

This Presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of QT Imaging Holdings, or any of its affiliates, nor shall there be any sale, issuance or transfer of securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale would be unlawful. You should not construe the contents of this Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision.

On June 6, 2017, the U.S. Food and Drug Administration ("FDA") in response to QT Imaging's Section 510(k) Summary of Safety and Effectiveness premarket notification under the Food, Drug and Cosmetic Act, determined that the QT Breast Scanner is substantially equivalent to the predicate device. Our use of the words "safe", "safety", "effectiveness", and "efficacy" in relation to the QT Breast Scanner in this Presentation and all other QT Imaging related documents is limited to the context of the Section 510(K) Summary of Safety and Effectiveness that was reviewed and responded to by the FDA.

TRADEMARKS AND INTELLECTUAL PROPERTY

All trademarks, service marks, and trade names of QT Imaging Holdings or its affiliates used herein are trademarks, service marks, or registered trade names of QT Imaging Holdings or its affiliates, as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners, and their use is not intended to, and does not imply, a relationship with QT Imaging Holdings or its affiliates, or an endorsement or sponsorship by or of QT Imaging Holdings or its affiliates. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that QT Imaging Holdings or its affiliates will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names.

Disclaimer

FORWARD LOOKING STATEMENTS

Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "has the potential to", "believe", "may", "will", "estimate", "continue", "anticipate", "intend", "expect", "should", "would", "plan", "predict", "potential", "seem", "seek", "future", "outlook", and similar expressions that indicate or predict future events or trends that are not statements of historical matters. These forward looking statements include, but are not limited to, the potential impact on existing medical technology, the company's technology, including, the evolution of QT Imaging into a scalable imaging platform combining proprietary hardware, advanced image reconstruction software, and AI-powered clinical decision tools to address the growing need for precision in breast health and the performance of software enhancements, product offerings, including QTI Cloud Platform and SaaS pricing model, business prospects, revenue, client adoptions, commercialization, including in Saudi Arabia, timing of reimbursement codes, projections of market opportunity, regulatory approvals and statements regarding estimates and forecasts of other financial and performance metrics. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of QT Imaging Holdings' management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not circumstances intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. In addition, statements regarding the Company's products, technology, and market opportunity reflect the beliefs and opinions of QT Imaging Holdings' management on the relevant subject as of this Presentation. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of QT Imaging Holdings. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; risks related to the rollout of QT Imaging Holdings' business and the timing of expected business milestones; the demand for QT Imaging Holdings' products and services; the ability of QT Imaging Holdings to increase sales of its output products in accordance with its plans; issues that could arise with respect to the manufacture of QT scanners by CMSC; the desire of customers and service recipients to continue engaging QT Imaging Holdings; the effects of competition on QT Imaging Holdings' future business, changes in the Company's strategy, future operations, financial positions, and product development timeline. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that QT Imaging Holdings presently does not know or believes is immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect QT Imaging Holdings' expectations, plans or forecasts of future events and views as of the date of this Presentation. QT Imaging Holdings anticipates that subsequent events and developments will cause its assessments to change. However, while QT Imaging Holdings may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing QT Imaging Holdings' assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Disclaimer

NON-GAAP FINANCIAL MEASURES

This presentation includes references to EBITDA and Adjusted EBITDA, financial measures that have not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). EBITDA is defined as loss before interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for equity-based compensation, net change in fair value of the derivative, earnout and warrant liabilities, and transaction expenses. Similar excluded expenses may be incurred in future periods when calculating these measures. QT Imaging believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. QT Imaging believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends and in comparing QT Imaging's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Investors should not rely on any single financial measure to evaluate QT Imaging's anticipated business. Certain of the financial metrics in this presentation can be found in QT Imaging's Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on May 13, 2025, and the reconciliation of EBITDA and Adjusted EBITDA can be found on pages 65 and 66 of this presentation.

QT Imaging Holdings (QTI) Has the Potential to Transform Medical Imaging

- QTI is a medical device company with imaging technology that has the **potential to transform the industry**
- QTI Scanner is **the only 3D imaging device to receive FDA clearance** for use as a transmission and reflection ultrasonic imaging system of a patient's breast

- QTI's patent-protected technology provides a high resolution, relatively low-cost, comprehensive, no radiation, no discomfort medical imaging solution
- QTI's technology **yields improved diagnostic performance compared to traditional mammogram** and has **similar imaging quality compared to MRI** but is a lower cost and **more accessible solution.**



Our Mission

Transforming Breast Health For Every Woman






At QT Imaging, we are redefining what's possible in breast imaging - **delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short.** Our goal is to make advanced diagnostic imaging **accessible to all women, including those with dense breast tissue or limited access to care.** With a platform rooted in innovation, clinical validation, and Artificial intelligence (AI) integration, we are committed to building a future where early, **accurate breast cancer detection is available without compromise.**



NIH has awarded QT Imaging about **\$18 Million** for a supplemental imaging solution for women with dense breasts

Our Management Team



History of QT Imaging



2012

Company founded by John Klock, MD



2012-2025

\$18M from NIH to develop supplemental imaging modality to resolve dense breasts



2017

FDA Clearance



Mar 2024

QTI becomes public on NASDAQ



Feb 2025

QTI gets delisted, public on OTC



Aug 2025


Raise \$18M



Oct 2025

NASDAQ application to relist by EOY 2025

QTI's Platform Approach



Versatile Clinical Use:

from early evaluation to diagnosis and treatment monitoring

AI-Ready Foundation:

continuous learning to improve diagnostic accuracy

Data-Rich Biomarkers:

speed-of-sound maps for tissue characterization

Upgradable & Scalable Platform:

software-defined features that adapt to evolving needs

Accessible & Affordable Design:

suitable for low-resource settings, mobile clinics, and underserved populations

Executive Summary

Patent-protected technology:

14 granted patents in US/Europe + 2 new patent applications

TECHNOLOGICAL CONSIDERATIONS

- FDA cleared for breast Imaging
 - **Breakthrough Device Designation awarded by the FDA** provides fast track to unique CPT codes and future clearances
- Based on safe waves, with the following biomarkers:
 - **Quantitative measure of the intrinsic speed of sound in Breast Tissue**
 - **Quantitative measurement of fibroglandular density ratio (breast density)**
- Standardized scanning with **operator independent images**, unlike hand-held ultrasound (HHUS)
- **Resolution comparable to MRI but without any contrast agent**
- **Volumetric accuracy** to determine mass doubling times
- **Higher diagnostic accuracy in Dense Breasts**

PATIENT CONSIDERATIONS

- **Safe, no radiation, no contrast**
- No discomfort, painless scans
- **Less recalls**, reduced anxiety
- **Less unindicated Intervention, Biopsy**
- Reduce cost of Care
- Scanning of women **under 40 years not suitable for Mammography**
- **Useful for Cancer Therapy Monitoring**


Quantitative Transmission (QT) Imaging

- What is QT Imaging?

- Inherently 3D volumetric imaging modality due to **3D data acquisition and mathematical image reconstruction, thus its high resolution, similar to MRI**
- Two independent sources of information:
 - Uses CT-like configuration with ultrasound to acquire and reconstruct **transmission images** which map the **speed-of-sound across the tissue volume (unique to our technology)**
 - Uses reflection configuration for **high-resolution depiction of tissue interfaces** (ducts, Cooper's ligaments, lesion boundaries) as well as **improved lesion visualization** — (cancers have irregular, heterogeneous reflective signatures)
- Overcomes **operator dependence and lack of standardization** associated with HHUS
- **Pain free, safe, no radiation or contrast**


- Image Acquisition:

- Prone position with breast submerged in water
- 360-degree rotation of ultrasound arrays
- 10-12 minutes per breast average scan time



Optimized Patient Experience

- **No ionized radiation.** Acoustic source only
- **No breast compression** and associated discomfort
- 10-12 minutes per breast exam time
- Quiet and comfortable (as compared to MRI - claustrophobia, coil pressure, noise and lengthy exams)
- **No contrast injection or associated risk**
(as compared to MRI Gadolinium)
- **No limitations for dense breasts or implants**



What's Next?



Biomarker Development

- Quantitative parameters: Speed of Sound, Attenuation, Reflection, Nakagami parameters etc.
- AI/ML models trained on large, labeled datasets
- Validation through retrospective analysis and clinical-grade ground-truth annotations



Cloud-Based All Integration

- Deployment within QTI Cloud SaaS Integration via InteleShare's framework
- Automated pipelines for image reconstruction, feature extraction, Probability of Cancer Map generation
- Continuous learning from clinical data uploads and feedback loops



Clinical Decision Support

- Visualization in QTviewer and clinician-facing dashboards
- Automated lesion segmentation and BIRADS scoring
- FDA validation and CPT reimbursement readiness
- Cloud-delivered AI updates with no on-premise installs required

What's Next


Why Biomarkers Matter for QT Imaging?

From Images to Quantitative Data

- Traditional breast imaging (mammography, MRI, ultrasound) produces **qualitative visual** information that **relies heavily on radiologist interpretation** rather than objective tissue properties
- QT Imaging's acoustic CT technology generates **quantitative volumetric maps of** speed of sound, attenuation coefficient, reflection intensity
- These measurable parameters serve as biophysical **biomarkers**, thus enabling **reproducible and repeatable features of tissue composition and structure**

Objective, Reproducible, and AI-Ready

- Biomarkers transform imaging from qualitative observation to **objective** science
- They provide **numeric indicators** of tissue stiffness, density, and microstructure
- Enable **machine learning** algorithms to detect subtle disease patterns
- Reduce inter-reader variability and **allow longitudinal tracking** of change over time



What's Next

Why Biomarkers Matter for QT Imaging?

Clinical Utility

Biomarkers allow QT Imaging to move beyond detection toward **diagnostic and prognostic precision** through **quantitative imaging**:

- **Early detection** of malignancy using defined quantitative thresholds
- **Therapy monitoring** such as pathological complete response (pCR) prediction in neoadjuvant therapy
- **Personalized medicine**, by correlating imaging biomarkers with genomic and histopathologic data
- **Automated lesion characterization** and BI-RADS aligned standardization for consistent interpretation



Clinical Value Proposition

Clinician	Challenges	QT Solution
Radiologist	Dense breast triage, reduce recalls and false positives	Dense breast image quality powered by quantitative geometric, spectral and elastic biomarkers will allow for better triage, increased physician confidence and reduce recalls and false positives
Radiologist oncologist	Breast preservation RT, precision dose delivery and tailoring of therapy	Precision image quality and quantitative biomarkers will allow for better biology guided radiation therapy
Medical oncologist	Personalizing therapy, therapy monitoring and management of side effects	Precision phenotyping powered by quantitative biomarkers will allow for better personalizing of therapy, monitoring and management
Surgeon	Accurate surgical planning, reducing risks	Higher image quality combined biomarker driven precision phenotyping (correlated with histopathologic data) will allow for better surgical planning and risk management

From a Hardware Company...


By building a biomarker-driven platform,
QT Imaging shifts from a hardware company to a
**precision imaging platform combining hardware,
software, and cloud-based AI modules**



Hardware
3D acoustic scanner



Software
reconstruction, denoising, analytics



Cloud AI
biomarker extraction,
disease probability maps

**To a Sustainable, Data-Centric Ecosystem
Continuously Improving with Clinical Use**



Business,
Partnerships,
and Footprint



Business Partnerships – Today



Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S.A. market



Under Contract Manufacturing Agreement with Canon Medical Systems – For Canon Distribution



شركة الخليج الطبية المحدودة
GULF MEDICAL CO. LTD.

Under Distribution Agreement with Gulf Medical for KSA (Kingdom of Saudi Arabia) market



Medical Image Management Archiving/communication systems and Cloud PACS partner

Business Partnerships



- Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S.A. market

- Committed quarterly minimum order quantities (MOQs) for scanners' shipments till end of 2026

2025	Q1	Q2	Q3	Q4	
	6	10	12	12	40

2026	Q1	Q2	Q3	Q4	
	13	15	15	17	60

- Four additional distributors signed by NXC Imaging to cover sales across all states

- Committed quarterly minimum order quantities (MOQs) for scanners' shipments 2026-2028

2026	Q1	Q2	Q3	Q4	
	5	5	5	5	20

2027	Q1	Q2	Q3	Q4	
	5	5	5	5	20

2028	Q1	Q2	Q3	Q4	
	5	5	5	5	20



- Under Contract Manufacturing Agreement with Canon Medical Systems
 - In the process of bringing up large scale manufacturing with CMSC in Japan
 - QTI Novato site to continue manufacturing scanners



شركة الخليج الطبية المحدودة
GULF MEDICAL CO. LTD.

Business Model – HW + QTI Cloud Platform

On Premise



Intelerad.

Radiology

Referring MD

QTI Cloud SaaS



QTI Cloud Platform plans to offer advanced breast analysis, predicting breast cancer risk with AI precision

- **Lesion-by-lesion detail**
Precision phenotyping for each lesion with biomarker based quantification and lesion risk scores
- **Comprehensive breast health assessment**
At-a-glance view of characterized breast health by region
- **Lesion scoring**
Clear and concise summary of identified lesions by severity to facilitate personalized treatment
- **Backed by clinical evidence**
To improve prognostic value, increase physician confidence and reduce false positives (unnecessary interventions and anxiety)

QT Scanner Locations Map

JAPAN



NORTH AMERICA



COMMERCIAL CENTERS

Center For New Medicine

Dr. Leigh Erin Connealy
6 Hughes, Suite 100
Irvine, CA 92618
+1 (949) 680-1880
[Website](#)

Longevity RX

Dr. Joel Fuhrman
Rancho Santa Fe, CA
+1 (858) 367-3558
[Website](#)

Couri Center for Gynecology and Integrative Women's Health

Dr. Michele Couri
6708 N Knoxville Ave, Suite 1
Peoria, IL 61614
[Website](#)

Innovative Radiology

Dr. John Tentinger
7601 Office Plaza Dr, Ste 115
West Des Moines, IA 50266
+1 (515) 222-0550
[Website](#)

PerfeQTion Imaging

Dr. Jenn Simmons
346 W Lancaster Ave,
Haverford PA 19041
[Website](#)

Qlarity Breast Imaging

Dr. Kristine Burke
3 Hamilton Landing #180
Novato, CA 94949
+1 (415) 842-7403
[Email](#)

Qlarity Breast Imaging

Dr. Kristine Burke
True Health Center for Precision
Medicine
8105 Saratoga Way, #240
El Dorado Hills, CA 95762
+1 (916) 542-1644
[Website](#)

Qlarity Breast Imaging

Dr. Yvonne Karney
Vitality Renewal Functional
Medicine
31 N. Virginia St.
Crystal Lake, IL 60014
+1 (815) 271-7300
[Website](#)

Robinhood Integrative Health

Dr. Wiggy Saunders
3288 Robinhood Rd.
Suite 202
Winston-Salem, NC 27106
+1 (336) 768-3335
[Website](#)

Vincere Cancer Center

Dr. Vershalee Shukla and Dr. Pablo
Prichard
Top Cancer Center in Scottsdale,
AZ
Vincere Cancer Center
7469 E Monte Cristo Ave.
Scottsdale AZ 85260
+1 (480) 306-5390
[Website](#)

CLINICAL SITES

Mayo Clinic

Tiffany Sae-Kho, M.D.
200 First Street SW
Rochester, MN 55905
+1 (855) 776-0015
[Website](#)

National Institutes of Health (NIH)

9000 Rockville Pike
Bethesda, MD 20892
United States

Sunnybrook Health Sciences Center (NIH Grant)

2075 Bayview Ave
North York, ON M4N 3M5
Canada


Prestigious University

in Tokyo, Japan

Quantitative Transmission Imaging – Why and How It Fits In



QTI's Technology Has the Opportunity to Transform the Breast Imaging Market

CURRENT MARKET		Layer	Description	2025 Value	2030 Value	CAGR	NEW MARKET						
Breast Imaging: \$6B MARKET ⁽¹⁾							SaaS Biomarkers: \$1B MARKET ⁽³⁾						
<ul style="list-style-type: none">FDA approved as supplementary screening device for breast imagingAim to revolutionize current imaging paradigm, replacing mammography, ultrasound (handheld and automated), and freeing MRI scanners time		TAM	Total global opportunity (dense-breast supplemental screening ⁽⁴⁾ + biomarkers ⁽³⁾)	2.5	3.8	8.5%	<ul style="list-style-type: none">Move to precision diagnosticsMove to personalized treatments with therapy guidance and monitoring						
		SAM	Accessible reimbursed markets (U.S., OECD, Korea, Japan) ⁽²⁾	1.7	2.6	8.5%							
		QTI Penetration	~10% SAM share by 2030	0.02	0.20–0.25	—							

(1) <https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market>


(2) <https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market> \$5.45B for 2024 with 8.9% CAGR.

(3) <https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622>

(4) <https://www.cdc.gov/breast-cancer/about/dense-breasts.html>

QT Imaging's FDA-cleared Solution for Dense Breasts

Many Women Have Dense Breasts, Which Mammograms are Inefficient in Screening for Cancer



50% of women between the ages of 40-74 in the US have dense breasts⁽¹⁾

In ~84% of cases observed in a recent mini-study, QT Scanner identified abnormalities in dense breasts that were not identified by x-ray mammograms⁽²⁾



The FDA Has Recognized the Importance of Breast Density in Breast Cancer Screening

Mammograms Must Include Breast Density Information, New FDA Rule Says

About half of the women over the age of 40 in the U.S. have dense breast tissue, which can make cancer scans hard to read⁽³⁾



"the new rule advises physicians and patients to consider breast density alongside other cancer risk factors when deciding whether additional screening is necessary"

– Hilary Marston,
CHIEF MEDICAL OFFICER, FDA

Mammography Misses **35.6–52.2%** of Breast Cancers in Dense Breast Tissue⁽⁴⁾

(1) Breast Density on a Mammogram, Susan G. Komen


(2) QTI Study | Dense Breast Mass Detection

(3) "Mammograms Must Include Breast Density Information, New FDA Rule Says". Wall Street Journal

(4) The Role of Ultrasound in Screening Dense Breasts. NCBI.

The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs

Screening compliance is low



25% women do not get regularly screened and 35% of women with greater health related social needs⁽¹⁾

- Do not follow guidelines
- Follow guidelines


Of the **65%** of women who do get screened, many suffer through unnecessary callbacks

Aside from the discomfort of the mammogram procedure, **up to 15% of women are called back** for additional procedures such as ultrasound, MRI or biopsies – which can be **expensive, time consuming and cause significant anxiety**⁽²⁾

For every **1,000** screening mammograms:

CALL BACK RATES
~15% call-backs rates with mammography

150



98% of Recalls are Avoidable

BIOPSIES
~10% biopsy rate for callbacks

15



Over 80% of Callback Biopsies are Benign⁽⁴⁾

CANCER INCIDENCE
0.3% cancer diagnosis⁽⁵⁾

3



(1) Mammography. Center for Disease Control and Prevention

(2)Very Well Health | 13 Reasons for a Mammogram Callback | Larell Scardelli


(3)PubMed | False-Negative Rate of Combined Mammography and Ultrasound for Women with Palpable Breast Masses | Carlos H.F. Chan, Suzanne B. Coopey, Phoebe E. Freer, and Kevin S. Hughes

(4)National Breast Cancer Foundation | Breast Biopsy: Procedure Types, What to Expect and Results

(5)U.S. Breast Cancer Statistics. Breastcancer.org.

Standard of Care Today^{1,2}

How QT Scan Fits In



Current Standard of Care in Breast Imaging

Risk Category	Lifetime Risk	Breast Density	Recommended Imaging Modalities	Guideline Recommendations
Average Risk	≤12–15%	Fatty Breasts	Screening Mammography (2D or 3D) annually starting at age 40	NCCN ⁽⁴⁾ : Annual mammography for women aged 40 and older. ACR/SBI ^(1,2) : Annual mammography starting at age 40. EUSOBI ⁽³⁾ : Biennial mammography for women aged 50–69; consider starting at 40.
Average Risk	≤12–15%	Dense Breasts	Screening Mammography (2D or 3D) annually starting at age 40 Supplemental Imaging: Consider Ultrasound or MRI	NCCN : Consider supplemental imaging for women with heterogeneously or extremely dense breasts. ACR/SBI : Recommend supplemental MRI for women with dense breasts and additional risk factors. EUSOBI : Recommend MRI screening every 2–4 years for women aged 50–70 with extremely dense breasts.
Above Average Risk	15–19%	Any Density	Screening Mammography (2D or 3D) annually starting at age 40 Supplemental Imaging: Consider MRI or Ultrasound	NCCN : Annual mammography; consider MRI for women with a 20–25% lifetime risk. ACR/SBI : Recommend MRI for women with a 20–25% lifetime risk. EUSOBI : MRI screening for women with a 15–20% lifetime risk.
High Risk	≥20–25%	Any Density	Screening Mammography (2D or 3D) annually starting at age 30 Supplemental Imaging: Annual MRI starting at age 25–30	NCCN : Annual MRI and mammography for women with ≥20% lifetime risk. ACR/SBI : Recommend annual MRI and mammography for women with ≥20% lifetime risk. EUSOBI : Recommend annual MRI for women with BRCA mutations or equivalent risk.

(1) J Am Coll Radiol. 2023 Sep;20(9):902-914.

(2) J Am Coll Radiol. 2024 Jun;21(6S):S126-S143

(3) Eur Radiol. 2024 Oct;34(10):6348-6357

(4) J Natl Compr Canc Netw. 2023 Sep;21(9):900-909

QTI's Current Indications For Use

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration	Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 <i>See PRA Statement below.</i>
Indications for Use	
510(k) Number (if known) K220933	
Device Name QT Scanner 2000 Model A	
Indications for Use (Describe) The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value. The device is not intended to be used as a replacement for screening mammography.	
The QT Scanner 2000 Model A is indicated for use by trained healthcare professionals in environments where healthcare is provided to enable breast imaging in adult patients.	

Broad intended use to allow breast imaging of any subject of age 18 or older

First FDA clearance for an ultrasound-based device to be able to quantify breast tissue volume


How QTI Potentially Fits Into the Current Paradigm

Risk Category	Potential Role of QTI Device
Average Risk (≤12–15%)	QTI offers a non-ionizing, high-resolution alternative for supplemental imaging, especially useful in patients with dense breasts where mammography is limited. Ideal for frequent monitoring without radiation exposure.
Above-Average Risk (15–19%)	QTI provides a safer alternative to MRI for moderate-risk individuals , including those with family history or dense tissue. It avoids gadolinium-based contrast risks, offering functional imaging with fewer contraindications.
High Risk (≥20–25%)	QTI may supplement or replace MRI in high-risk individuals, especially where MRI is contraindicated or poorly tolerated. Supports early, radiation-free surveillance with improved soft-tissue contrast, aligning with early screening needs.

Patient's Clinical Journey



< 40 Yrs



> 40 Yrs




Patient's Clinical Journey



< 40 Yrs



> 40 Yrs





Quantitative Transmission Imaging – Dense Breast Center of Excellence



The Challenge with Dense Breast Imaging



Primary Screening

Supplemental Screening

Biopsy & Diagnostic Imaging

Multiple Scheduling, Patient Attrition, Patient Anxiety, Operator Variability
Radiation, Compression, Contrast

Our Solution for Women with Dense Breast

QT Supplemental Screening



Biopsy & Diagnostic Imaging



Less Scheduling, Less Patient Attrition, Less Patient Anxiety, No Operator Variability
No Radiation, No Compression, No Contrast

For the Patient

- Multi-scheduling
- Radiation, compression, contrast
- High recall, operator dependency



Breast Density Confirmation

- One-stop-shop
- No radiation, no compression, no contrast
- Low recall, operator independent



For Clinician

- Dense breast lesion conspicuity challenges reading two tests, resolving operator variability
- High recalls leading to additional tests
- MR-like imaging

- One test – multiple results (DCIS + Ca, Density, Doubling, Cyst/Solid, Implant)
- Reflection, speed of sound, attenuation & breast density measure (FGR) biomarkers
- Low recall, operator independent




For Administrator

- Revenue capped to mammo & supplemental
- High labor costs requiring specialized technologists
- Capex includes equipment, siting, shielding
- **5-year investment recovery with 10 patients/day**


- 2 X More revenue per scan
- 1/3 Annual Labor – nonspecialized personnel
- Capex – Comparable equipment costs, lower siting costs
- Comparable Annual Service
- Reduced overheads with one stop shop
- **3-year investment recovery with 3-4 patients/day**




Invasive Ductal Carcinoma in Left Breast- Case 1




XRM



HHUS




MRI




QTscan

QTscan has the quality and resolution of the MRI image, with no need for contrast IV


Invasive Ductal Carcinoma in Left Breast- Case 2




XRM



HHUS




MRI




QTscan


Invasive Ductal Carcinoma in Left Breast - Case 3




XRM · Neg



HHUS · Neg




MRI




QTscan

MR-Like Imaging




Mammography




3D Mammography
with Tomosynthesis



Hand-held
Ultrasound




Breast MRI




QTscan

Same breast imaged using five different imaging modalities


MR Like Imaging




Mammography



Hand-held
Ultrasound




Breast MRI




QTscan

Dense Breast with DCIS




Calcifications in Functional Imaging

Patient on Tamoxifen for DCIS




16 Jan 2020 Calcium = 77.8 mm³




19 Jan 2022 Calcium = 19.5 mm³

Micro-Cyst

Speed of Sound = 1540 m/s



Saline Implant Rupture: Folded Implant



Silicone Implant Rupture: Sub-capsular Silicone (Dark Areas)


(REPROCESSED)COMMERC
REFLECTION
5/3/2019 3:03 PM
Acc: LEFT BREAST
Lat: L

S

F

M

L



Cancer in Breast with Implant

(REPROCESSED)COMMERC

SPEED OF SOUND

5/10/2019 12:14 PM

Acc: LEFT BREAST

Lat: L

P

S



Lobular Carcinoma

(REPROCESSED)COMMERC

SPEED OF SOUND

6/4/2019 4:08 PM

Acc: RIGHT BREAST

Lat: R

L

P

MBH Q1bH

(REPROCESSED)COMMERC

SPEED OF SOUND

6/4/2019 4:08 PM

Acc: RIGHT BREAST

Lat: R

M

A

Ax

QBD: 20

W 256 m/s : L 1472 m/s

M

I

A


QBD: 20

W 256 m/s : L 1472 m/s


A

Ductal Carcinoma

Cyst vs. Solid Identification Using Speed of Sound



Cyst



Solid


Top panel = 3 transmission images

Bottom panel = 3 reflection images


3 planes from left to right: coronal, axial and sagittal

Speed of Sound in Transmission Images


- Each voxel has a Speed of Sound value
- A “speed map” is created
- Can serve as a biomarker to distinguish tissue types



Dense Breast Imaging – Reduce False Negatives



Case 6 Cyst (109R)



Case 7 Cyst (089R)

Speed of Sound Guides

Breast Tissue Speeds (Mean \pm SD)




Table 1. Estimated Probability of a Cyst/Solid Lesion as a Function of the Speed of Sound Value from a Prior Internal Feasibility Study

Speed of Sound Value (m/s)	Probability That the Lesion Is a Cyst (%)	Probability That the Lesion Is a Solid (%)
≤ 1540	0.91-0.98	0.02-0.09
1541-1560	0.89-0.98	0.02-0.11
1561-1570	0.23-0.64	0.36-0.77
1571-1580	0.01-0.06	0.94-0.99
> 1580	<0.01	>0.99




Probabilities are applicable to populations with a prevalence rate between 0.40 and 0.80.

Accurate and Repeatable Segmentation

- Fibroglandular Ratio (FGR) provides a quantitative breast density

$$FGR = \frac{\text{Fibroglandular volume}}{\text{Total breast volume}} \times 100$$


- Fibroglandular Ratio correlates with Volpara™ Density grades
- Can be used to determine doubling time



Rajni Natesan, James Wiskin, Sanghyeb Lee, Bilal H. Malik; Quantitative Assessment of Breast Density: Transmission Ultrasound is Comparable to Mammography with Tomosynthesis. *Cancer Prev Res (Phila)* 1 December 2019; 12 (12): 871-876. <https://doi.org/10.1158/1940-6207.CAPR-19-0268>

NOTE: The term quantitative breast density (QBD) reference in this publication is now FGR.

Functional Imaging - Doubling Time




- Intended to confirm that a mass is stable, increasing, or shrinking
- Designed to reduce unneeded false positive biopsies and reduce call-back visits
- Biopsy is still required to confirm cancer diagnosis




Competitive
Landscape



The QT Scanner Delivers a Better Experience for Patients than Traditional Systems




Imaging Accuracy in Breast Mass Diagnosis⁽¹⁾




(1) Based on opinion of QT Imaging Holdings team.

(2) Quantitative tissue/density characterization means assessment of quantitative/volumetric breast density. Other than Mammography and QT1, there are no FDA cleared algorithms for volumetric density assessment.

QTI Provides High Resolution, Similar to MRI



~200,000
times more data
per voxel than
 (N_{MRI})



QT redundancy of data means:

- Similar collection time and resolution
- Higher detection capability
- Higher Signal-to-Noise (without Gadolinium or other contrast)
- Repeatable quantitative measurements
- Quantitative and morphological biomarkers for longitudinal studies

(1) Y. Gao and S. L. Heller, "Abbreviated and Ultrafast Breast MRI in Clinical Practice," *RadioGraphics*, vol. 40, pp. 1507-1527, 2020

Note: Voxel is a 3D version of a pixel



Specific
Reimbursement
Codes




Coding Pathways for QT Imaging

- Current State:
 - Use **CPT 76999** (unlisted ultrasound procedure)
 - QTI provided a 'guidelines' document for providers and patients (at www.qtimaging.com)
- Strategy / Next Steps:
 - **New Tech APC application** – Submitted August 2025
 - Expected Category C-code by Q1 2026
 - **Category III CPT code** (early commercialization)
 - Submitted on 11/3/2025
 - Expected Cat III code by Q1 2027

New Tech APC: New technology ambulatory payment classification (APC) – temporary payment groups to provide reimbursement for new medical technologies or services. Allows interim payment while payers evaluate the technology's use and cost.



Regulatory Activities



Regulatory Activities

Saudi FDA (SFDA)



Submit Dossier —Jan 1, 2026
Authorized Rep via Gulf Medical;
MDS-GS-004

Regulatory Review
Anticipated
60–90 days

Expected Marketing
Authorization
Target: Q2 2026

UAE MOHAP



Dossier Preparation
Leverage SFDA submission;
MOHAP registration

UAE Submission
MOHAP device
registration

Expected Approval
Target: Q3 2026

CE Mark (EU MDR)



Notified Body Engagement
BSI/Alternate;
plan conformity route

Submit Technical
Documentation
CER, Annex II/III,
PMS/PMCF

Expected CE Mark
Target: Q4 2026



What's Next?




From a Hardware Company...


By building a biomarker-driven platform,
QT Imaging shifts from a hardware company to a
**precision imaging platform combining hardware,
software and cloud-based AI modules**



Hardware
3D acoustic scanner



Software
reconstruction, denoising, analytics



Cloud AI
biomarker extraction,
disease probability maps

...To a Sustainable, Data-Centric Ecosystem
Continuously Improving with Clinical Use

Investment Highlights

Industry-Transforming, FDA Cleared (Breakthrough Device Designation) Imaging Technology Platform Recognized by Industry Incumbents



True 3D, Quantitative, High Resolution (Comparable to MRI) Breast Imaging Technology, with No Discomfort or Contrast Agents



Higher Specificity and Improved Non-Cancer Recall Rates Compared to Traditional Mammogram, under Favorable Safety Profile



QT IMAGING

HW + Cloud SaaS Platform/Biomarkers Pipeline Business Model



High-Value Entry in \$6B+ Breast Imaging Market



Strategic Partnerships for Distribution in USA and Saudi Arabia and Scalable Manufacturing



Strong Commercial Momentum with \$18M (in USA) and \$39M (in USA and Saudi Arabia) in Contracted Revenue in 2025 and 2026 respectively



Q3'25 Financials



Financial Highlights for Q3'25

- On October 3, 2025, **we closed a over subscribed \$18.2 million private placement financing**, which included anchoring from Sio Capital and participation from other institutional and existing company investors.
- On August 26, 2025, **we received \$5.0 million in additional funding** via a restated and amended senior secured term loan with Lynrock Lake, which allowed for the **repurchase of the Yorkville warrant for \$5.0 million. The \$5.0 million was repaid to Lynrock Lake in October 2025.**
- **Commercial revenue was \$4.2 million during the third quarter of 2025**, representing 339% year-over-year growth and 15% sequential quarter-over-quarter growth. The year-over-year increase in revenue was primarily attributable to the shipment of nine QT Breast Acoustic CT™ scanners during the third quarter of 2025, as per minimum order quantities ("MOQs") in the Company's Distribution Agreement with NXC Imaging, as compared to two scanners sold in the third quarter of 2024. In addition, the Company has shipped five more scanners during the month of October 2025, for a total of 28 scanners, in agreement with its distribution agreement.

Financial Highlights for Q3'25 QTD

- **Gross margin of 43% in the third quarter of 2025**, compared to gross margin of 63% in the second quarter of 2024
 - The decline in gross margin in the third quarter of 2025 was primarily attributable to variability in the weighted average cost related to the Company's existing inventory.
- **Net loss of \$4.6 million for the third quarter of 2025**, compared to net loss of \$3.6 million for the third quarter of 2024. Q3'25 net loss included:
 - \$2.3 million of net non-cash expense related to the change in fair value of earnout and warrant liabilities
 - \$0.2 million of stock-based compensation expense
- **Non-GAAP Adjusted EBITDA of \$(1.4) million for the third quarter of 2025**, compared to \$(2.2) million for the third quarter of 2024.

Financial Highlights for Q3'25 QTD

- **Ended Q3'25 with \$1.7M in cash, compared to end of Q4'24 with \$1.7M in cash. Cash flows from operating activities was \$5.9 million year-to-date in 2025, and cash flows from financing activities was \$6.4 million**, including \$15.0 million proceeds from the restated and amended senior secured term loan with Lynrock Lake, \$5.0 repurchase of the Yorkville warrant, and \$4.7 million repayment of the Yorkville and Cable Care notes.
- **Reiterated plans to deliver \$18 million in revenue in 2025 (shipment of 40 scanners).** The target is in accordance with the MOQs per our Amended Distribution Agreement with our strategic business and distribution partner, NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA.
- **The Company revealed plans to deliver \$39 million in revenue in 2026 (shipment of 80 scanners).** These targets are in accordance with the MOQs with the Distribution Agreement NXC Imaging in USA, as well as MOQs per our Distribution Agreement with Gulf Medical in Saudi Arabia, which was signed on August 27, 2025.

Summary of Q3'25 QTD GAAP Results

\$ thousands (except share and per share amounts)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenue	\$ 4,192	\$ 956	\$ 10,650	\$ 4,032
Cost of revenue	2,389	351	5,208	1,792
Gross profit	1,803	605	5,442	2,240
Operating expenses:				
Research and development	939	925	2,692	2,493
Selling, general and administrative	2,516	2,007	6,487	9,873
Loss from operations	(1,652)	(2,327)	(3,737)	(10,126)
Interest expense, net	(565)	(1,455)	(1,635)	(3,149)
Other (expense) income, net	(30)	17	(8,770)	(191)
Change in fair value of warrant liability	(80)	9	(3,581)	200
Change in fair value of derivative liability	—	87	101	4,800
Change in fair value of earnout liability	(2,230)	50	(2,070)	2,970
Loss before income tax expense	\$ (4,557)	\$ (3,619)	\$ (19,692)	\$ (5,496)
Income tax expense	—	—	3	—
Net loss	\$ (4,557)	\$ (3,619)	\$ (19,695)	\$ (5,496)
Less: deemed dividend related to the modification of equity classified warrants	—	—	—	(5,186)
Net loss attributable to common stockholders	\$ (4,557)	\$ (3,619)	\$ (19,695)	\$ (10,682)
Basic and diluted net loss per share (1)	\$ (0.47)	\$ (0.51)	\$ (2.09)	\$ (1.72)
Weighted average shares outstanding (1)	9,601,972	7,155,505	9,415,349	6,245,877

(1) Share and per share amounts for the three and nine months ended September 30, 2024 differ from those published in prior condensed consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1 to the condensed consolidated financial statements). Specifically, the number of shares of common stock outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 3:1, such that each three shares of common stock were combined and reconstituted into one share of common stock effective October 23, 2025.

Summary of Q3'25 QTD Non-GAAP Results

\$ thousands	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Net loss	\$ (4,557)	\$ (3,619)	\$ (19,695)	\$ (5,496)
Interest expense, net	565	1,455	1,635	3,149
Income tax expense	—	—	3	—
Depreciation and amortization	40	20	115	204
EBITDA	(3,952)	(2,144)	(17,942)	(2,143)
Adjustments:				
Stock-based compensation	199	127	519	166
Warrant modification	—	—	—	201
Debt modification and extinguishment expenses ⁽¹⁾	46	—	2,170	—
Change in fair value of warrant liability ⁽²⁾	80	(9)	3,581	(200)
Change in fair value of derivative liability ⁽³⁾	—	(87)	(101)	(4,800)
Change in fair value of earnout liability ⁽⁴⁾	2,230	(50)	2,070	(2,970)
Transaction expenses ⁽⁵⁾	—	—	—	4,301
Debt issuance expense ⁽⁶⁾	—	—	6,640	—
Adjusted EBITDA	\$ (1,397)	\$ (2,163)	\$ (3,063)	\$ (5,445)

Adjustments to EBITDA

- (1) The Company recorded debt modification expense of \$0.1 million primarily related to its modification of the Cable Car Note on January 9, 2025 and debt extinguishment expense of \$2.0 million related to the extinguishment of the Yorkville Note and Cable Car Note on February 26, 2025 in other (expense) income, net for the nine months ended September 30, 2025.
- (2) The increase in fair value of warrant liability during the nine months ended September 30, 2025 relates to the liability classified private placement warrants, the Lynrock Lake Warrant and Yorkville Warrant, which is primarily driven by increase in the Company's stock price from beginning of period to June 11, 2025, which is the date the Lynrock Lake Warrant and Yorkville Warrant were modified and subsequently reclassified to equity.
- (3) The decrease in fair value of derivative liability during the nine months ended September 30, 2025 related to the Yorkville Pre-paid Advance, which contained features that were bifurcated as freestanding financial instruments and initially valued on March 4, 2024 upon consummation of the Merger. The derivative liability was subsequently revalued as of February 26, 2025, prior to the extinguishment of the Yorkville Note.
- (4) The earnout liability relates to the contingent consideration for the Merger Earnout Consideration Shares pursuant to the Business Combination Agreement dated December 8, 2022, as amended in September 2023. The earnout liability was initially valued using the Monte Carlo Simulation method on March 4, 2024 and subsequently revalued using the same method.
- (5) The Company incurred transaction expenses related to the Merger with GigCapital5, Inc., which closed on March 4, 2024. These transaction expenses included a \$3.7 million of transaction costs that were settled with issuance of common stock, \$0.4 million of transaction costs settled or payable in cash and a \$0.2 million loss on issuance of common stock in connection with a subscription agreement, which were recorded as selling, general and administrative expenses in the condensed consolidated statement of operations during the nine months ended September 30, 2024. There were no transaction expenses incurred during the nine months ended September 30, 2025.
- (6) Upon the issuance of Lynrock Lake Term Loan closed on February 26, 2025, the Company recorded a loss of \$6.6 million, including debt issuance costs of \$0.2 million, in other expense, net for the nine months ended September 30, 2025.

Balance Sheets as of Q3'25 and Q4'24

\$ in thousands	September 30, 2025	December 31, 2024
Assets		
Current assets:		
Cash	\$ 1,715	\$ 1,172
Restricted cash and cash equivalents	20	20
Accounts receivable, net	3,244	67
Inventory	5,242	3,141
Prepaid expenses and other current assets	1,067	517
Total current assets	11,288	4,917
Non-current assets:		
Property and equipment, net	127	196
Operating lease right-of-use assets, net	667	935
Other assets	39	39
Total assets	\$ 12,121	\$ 6,087

\$ in thousands	September 30, 2025	December 31, 2024
Liabilities and Stockholders' Deficit		
Current liabilities:		
Accounts payable	\$ 2,019	\$ 803
Accrued expenses and other current liabilities	5,235	3,550
Current maturities of long-term debt	5,023	4,986
Deferred revenue	24	49
Operating lease liabilities, current	442	406
Total current liabilities	12,743	9,794
Non-current liabilities:		
Long-term debt	273	9
Related party notes payable	3,895	3,849
Operating lease liabilities	321	657
Warrant liability	106	22
Derivative liability	—	304
Earnout liability	2,510	440
Other liabilities	1,349	550
Total liabilities	21,197	15,625
Stockholders' deficit:		
Common stock (1)	1	1
Additional paid-in capital (1)	42,558	22,402
Accumulated deficit	(51,635)	(31,941)
Total stockholders' deficit	(9,076)	(9,538)
Total liabilities and stockholders' deficit	\$ 12,121	\$ 6,087

(1) Share amounts as of December 31, 2024 differ from those published in prior consolidated financial statements as they were retrospectively adjusted as a result of the Reverse Stock Split (as described below in Note 1, The Company and Summary of Significant Accounting Policies). Specifically, the number of shares of common stock outstanding during periods before the Reverse Stock Split are divided by the exchange ratio of 3:1, such that each three shares of common stock were combined and reconstituted into one share of common stock effective October 23, 2025.

Cash Flow Statements for Q3'25 YTD and Q3'24 YTD

\$ in thousands	Nine Months Ended September 30,	
	2025	2024
Cash flows from operating activities:		
Net loss	\$ (19,695)	\$ (5,497)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	115	204
Stock-based compensation	519	166
Warrant modification expense	—	201
Loss on issuance of the Lyrock Lake Term Loan	6,640	—
Debt extinguishment loss	2,080	—
Debt modification expense	90	—
Provision for credit losses	—	1
Fair value of common stock issued in exchange for services and in connection with non-redemption agreements	—	3,718
Loss on issuance of common stock in connection with a subscription agreement	—	206
Non-cash interest	749	2,404
Non-cash operating lease income	(31)	(21)
Change in fair value of warrant liability	3,581	(200)
Change in fair value of derivative liability	(101)	(4,800)
Change in fair value of earnout liability	2,070	(2,970)
Changes in operating assets and liabilities:		
Accounts receivable	(3,177)	(256)
Inventory	(2,102)	1,526
Prepaid expenses and other current assets	(298)	(459)
Accounts payable	1,072	(2,062)
Accrued expenses and other current liabilities	1,856	(768)
Deferred revenue	(25)	(328)
Other liabilities	799	129
Net cash used in operating activities	(5,858)	(8,806)

\$ in thousands	Nine Months Ended September 30,	
	2025	2024
Cash flows from investing activities:		
Purchases of property and equipment	(47)	(35)
Net cash used in investing activities	(47)	(35)
Cash flows from financing activities:		
Proceeds from sale of common stock and warrants, net of issuance costs	679	—
Proceeds from issuance of common stock pursuant to subscription agreement, net of issuance costs	—	500
Proceeds from long-term debt, net of issuance costs	15,000	10,525
Proceeds from stock option exercises	75	—
Proceeds from warrant exercises	532	—
Repayment of long-term debt	(4,688)	(1,243)
Repayment of bridge loans	—	(800)
Payment of deferred issuance costs	(150)	—
Proceeds from the Merger, net of transaction costs	—	1,238
Repurchase of warrant from Yorkville	(5,000)	—
Net cash provided by financing activities	6,448	10,220
Net increase in cash and restricted cash and cash equivalents	543	1,379
Cash and restricted cash and cash equivalents at the beginning of period	1,192	185
Cash and restricted cash and cash equivalents at the end of the period	\$ 1,735	\$ 1,564



Thank You!

